Trial Profile
Adoptive Immunotherapy for Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cells
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs TI-1007 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Timmune Biotech
- 31 Oct 2018 New trial record